SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: hoyasaxa who wrote (27056)6/11/2007 7:13:52 PM
From: Brinks  Read Replies (1) of 78667
 
Well I will be attending the Monogen shareholders meeting next week. Hope to share a dinner with the chief scientist. All the pieces of the foundation have been put in place. Key will be execution. Can they pull it off?????

I would hardly call investing $ 10 million in a company like Monogen a pump and dump. Realzing value here does require patience.

Read the 2006 Annual Report !!!!!!!!!!!!!!

Business Strategy(Taken from MonoGen's 2006 Annual Report)

MonoGen’s goal is to become the leading provider of a fully integrated automated platform for cytology and molecular diagnostics. Key elements in the Corporation’s strategy to achieve this goal include:

• Establishing the MonoPrep Processor as the leading cytology specimen processing system, especially in the large established gynecological market for cervical cancer screening;

• Launching new products to complete the SLS, a fully integrated automated platform for cytology and molecular diagnostics. Initially, MonoGen will be launching the MonoPrep Processor for non-gynecological and gynecological applications. MonoGen intends to introduce additional products to expand the SLS, including a MonoPrep Imaging System and BioSight Pathology Workstation; and

• Pursuing discussions with molecular diagnostics companies to allow these companies’ assays to be used with specimens collected in MonoPrep vials, such as HPV assays, in addition to potentially licensing the further development of lung and other cancer panel assays for which the Corporation has developed intellectual property.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News